Letko Brosseau & Associates Inc. Purchases 4,675 Shares of Illumina, Inc. $ILMN

Letko Brosseau & Associates Inc. increased its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 858,993 shares of the life sciences company’s stock after buying an additional 4,675 shares during the quarter. Illumina makes up about 1.8% of Letko Brosseau & Associates Inc.’s investment portfolio, making the stock its 16th largest position. Letko Brosseau & Associates Inc.’s holdings in Illumina were worth $112,666,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Focus Partners Advisor Solutions LLC boosted its holdings in Illumina by 6.3% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 23,032 shares of the life sciences company’s stock worth $3,021,000 after buying an additional 1,371 shares during the period. Waddell & Associates LLC boosted its holdings in Illumina by 19.3% in the 4th quarter. Waddell & Associates LLC now owns 4,468 shares of the life sciences company’s stock worth $586,000 after buying an additional 723 shares during the period. Fox Run Management L.L.C. bought a new position in Illumina in the 4th quarter worth $863,000. Cerity Partners LLC boosted its holdings in Illumina by 53.2% in the 4th quarter. Cerity Partners LLC now owns 192,091 shares of the life sciences company’s stock worth $25,195,000 after buying an additional 66,704 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Illumina by 435.5% in the 4th quarter. Franklin Resources Inc. now owns 328,857 shares of the life sciences company’s stock worth $43,133,000 after buying an additional 267,443 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.3%

Shares of ILMN stock opened at $160.03 on Wednesday. The stock has a market cap of $24.21 billion, a P/E ratio of 29.10, a PEG ratio of 2.96 and a beta of 1.50. Illumina, Inc. has a 52 week low of $85.00 and a 52 week high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company’s fifty day simple moving average is $139.27 and its two-hundred day simple moving average is $134.20.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ILMN. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Royal Bank Of Canada began coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Canaccord Genuity Group decreased their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Barclays boosted their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Finally, Citigroup boosted their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $138.38.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $98,400.00. Following the sale, the insider owned 21,568 shares in the company, valued at $3,450,880. This represents a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is owned by insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.